Intercept Downgraded To Sell From Neutral At H.C. Wainwright
February 23, 2021 at 08:22 AM EST
H.C. Wainwright analyst Ed Arce downgraded Intercept Pharmaceuticals to Sell from Neutral with a price target of $25, down from $46, after the company disclosed that its Chief Medical Officer Jason Campagna has decided to resign effective March 5.
